Update on HPV prophylactic vaccine
Wednesday, June 15, 2016
Oral Communications
•
OC 03
•
4:15 PM
>
5:30 PM
•
Update on HPV prophylactic vaccine
•
Wolf-Dietrich
Oral Communications
•
OC 03-01
•
Long-term protection of virus-like particle (VLP)- based human papillomavirus (HPV) vaccines
See abstract
>
A.
Alfred
Saah
•
OC 03-02
•
Persistence of immune response 10 years after administration of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine to women aged 15-55 years
See abstract
>
T.
Tino F
Schwarz
•
OC 03-03
•
A long-term effectiveness, immunogenicity, and safety study of Gardasil™ (human papillomavirus [types 6,11,16,18] recombinant vaccine) in young men (V501-020)
See abstract
>
A.
Alfred
Saah
•
OC 03-04
•
Immune responses after two-versus-three-dose immunization against HPV up to 4 ½ years post vaccination among Dutch routinely vaccinated girls (HPV-2D)
See abstract
>
T.
Tessa
Schurink-Van ’t Klooster
•
OC 03-05
•
No evidence of type replacement following HPV16/18 vaccination: Pooled analysis of data from the Costa Rica Vaccine and PATRICIA randomized trials
See abstract
>
J.
Joseph
Tota
•
OC 03-06
•
Health and Economic Impact of Vaccinating Boys in Addition to Girls against Oncogenic HPV in the Netherlands
See abstract
>
V.
Venetia
Qendri
•
OC 03-07
•
Overall impact of HPV vaccination strategies- a randomized trial
See abstract
>
M.
Matti
Lehtinen
•
OC 03-08
•
Decline in quadrivalent human papillomavirus infection in young sexually active heterosexual men with chlamydia trachomatis 8 years following the universal Australian female vaccination programme: implications for herd protection
See abstract
>
E.
Eric P.F.
Chow
|